AI Article Synopsis
- Current treatments for Alzheimer's aim to boost acetylcholine levels in the brain but lose effectiveness over time and can cause side effects like liver damage.*
- This research explores using low-dose acetylcholine delivered through human serum albumin nanoparticles, which showed improvements in learning and memory while reducing oxidative damage in mice.*
- The study suggests that this method of delivering acetylcholine could be a safer and more effective therapy for Alzheimer's compared to traditional approaches.*
Article Abstract
The current clinical symptomatic therapy for Alzheimer's disease involves increasing acetylcholine levels in the brain by inhibiting acetylcholinesterase. However, the effectiveness of acetylcholinesterase inhibitors decreases as the disease progresses, leading to many side effects including over-inhibition of other enzymes and hepatic injury. Herein, we investigate the effects of the direct delivery of a low-dose of acetylcholine via human serum albumin nanoparticles to brain. This novel nanodrug improved both spatial learning and memory capability, whereas it reduced oxidative damage in mice. More importantly, damage to the liver or interference with the inherent neurotransmitter generation due to supplementation were almost absent. Our study is the first to demonstrate that supplementation of acetylcholine-loaded nanoparticles might offer a better therapeutic option in the ease of Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1166/jbn.2018.2649 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!